Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Sure long-term durability follow-up study after prior bepirovirsen trials
jRCT2031210493Active, not recruiting
- Sponsor
- GSK
- Start
- Jan 2022
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Open-label trial of bepirovirsen in Chronic Hepatitis B (CHB) (2 arms), sponsored by GSK. Primary endpoints: Time to loss of functional cure, Not-on-NA participants without loss of parent study primary outcome and 3 more. Started Jan 2022; status: active, not recruiting.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on jRCT2031210493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210493.